Abstract 2676
Background
Oncology nurses are responsible to provide their patients with the evidence-based care. Clinical guidelines or recommendations can be developed by scientific associations as a guide for performing evidence-based practice. These guidelines are often taken into consideration for the assessment of professional responsibility, as well as to guide the practice. The Italian Institute of Health identified the Italian Association of Cancer Nurses (AIIAO) among the scientific societies authorised to produce, adapt and implement guidelines. However, it is important to identify which areas of oncology nursing warrant an action to facilitate AIIAO in setting the agenda. A specific prerequisite for developing high-quality guidelines is incorporating nurses’ views into priority-setting. The aim of this study is to use a bottom-up approach to empirically investigate which areas of oncology nursing require higher priority in the definition of evidence-based recommendations.
Methods
This is a multi-phase study including a cross-sectional national survey. In order to develop the tool for the survey, a systematic search of the literature, a focus group, and content and face validity evaluation will be conducted.
Results
Seven areas were identified by the literature review to develop the survey: (a) fatigue; (b) pain; (c) sleep disorders; (d) secondary symptoms; (e) cognitive impairment resulting from cancer and its treatment; (f) chemotherapy-induced peripheral neuropathy; and (g) psychological distress. This research is still ongoing. A panel of researchers are operationalising the identified areas in the items for the national survey. Cancer nurses will be asked to rate the priority of each area for the implementation, adaptation and development of AIIAO clinical guidelines.
Conclusions
The results of this survey might raise awareness about oncology nurses’ opinions on which areas of clinical practice warrant an action. This will facilitate the associations and affiliated working groups in developing evidence-based recommendations. Moreover, a bottom-up mapping of the nurses’ priorities will inform the planning of AIIAO strategic activities targeted to strengthen cancer care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Italian Association of Cancer Nurses (AIIAO).
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3524 - Cabazitaxel For Octogenarian Patients With Metastatic Castration-Resistant Prostate Cancer (MCRPC).
Presenter: Paolo Tralongo
Session: Poster Display session 3
Resources:
Abstract
5637 - External Validation of a Prognostic Score in First-Line Metastastic Castration-Resistant Prostate Cancer (mCRPC)
Presenter: David Lorente
Session: Poster Display session 3
Resources:
Abstract
3228 - Treatment outcomes of 3rd treatment in a real-world metastatic castration resistant prostate cancer (mCRPC) population: results from the Dutch CAPRI-registry
Presenter: Jessica Notohardjo
Session: Poster Display session 3
Resources:
Abstract
4695 - Pelvic lymph node dissection and its extent on survival benefit in prostate cancer patients with a risk of lymph node invasion>5%: a propensity score matching analysis from SEER database
Presenter: Junru Chen
Session: Poster Display session 3
Resources:
Abstract
4438 - Multi-institutional evaluation of therapeutic management for oligometastatic cancer prostate recurrence with choline-PET/CT
Presenter: Morgane Guibert-broudic
Session: Poster Display session 3
Resources:
Abstract
4574 - Safety of new androgen receptor inhibitors (ARi) in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC): a network meta-analysis of randomized controlled trials (RCT)
Presenter: Amelia Altavilla
Session: Poster Display session 3
Resources:
Abstract
3816 - Real-world use of radium-223 for treatment of metastatic castration resistant-prostate cancer (mCRPC): results from the Dutch CAPRI registry
Presenter: Malou Kuppen
Session: Poster Display session 3
Resources:
Abstract
5180 - A phase 2a study of radium-223 dichloride (Ra-223) alone or in combination with abiraterone acetate or enzalutamide in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Daniel Petrylak
Session: Poster Display session 3
Resources:
Abstract
1067 - Adding ADT to PSMA-PET/CT-guided SBRT for oligometastatic prostate cancer improves distant progression-free survival
Presenter: Carole Mercier
Session: Poster Display session 3
Resources:
Abstract
5529 - Safety and efficacy of Ac-225-PSMA-617 in metastatic castration resistant prostate cancer (mCRPC) after failure of Lu-177-PSMA
Presenter: Robert Tauber
Session: Poster Display session 3
Resources:
Abstract